focuses on supplying innovative non-invasive acoustic tools for disease management of asthma and related pulmonary disorders.
Asthma affects 6-16% of the population in developed countries with a cost exceeding $US15 billion in the US alone.
Acoustic Asthma Management is a breakthrough in monitoring of the asthmatic patient of all ages, including the very young, very old and others who cannot perform currently available tests.
The technology that comes from extensive R&D and clinical validation in the US, Israel and Australia, facilitate continuous monitoring of patients at home, in the ICU and even during sleep.
The company is focused on early commercialization of its products with special emphasis on the European and North American markets.
KSX Price at posting:
5.0¢ Sentiment: Buy Disclosure: Held
